Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13400121 | 1.00 | CA2 (0.32) | CA2MAPT | |
| SCHEMBL12532634 | 1.00 | CA2 (0.32) | CA2MAPT | |
| SCHEMBL13266323 | 1.00 | CA2 (0.32) | CA2MAPT | |
| SCHEMBL13832386 | 1.00 | CA2 (0.32) | CA2MAPT | |
| SCHEMBL20788826 | 1.00 | CA2 (0.32) | CA2MAPT | |
| SCHEMBL16730247 | 1.00 | CA2 (0.32) | CA2MAPT | |
| SCHEMBL15195755 | 1.00 | CA2 (0.32) | CA2MAPT | |
| SCHEMBL4022246 | 1.00 | CA2 (0.32) | CA2MAPT | |
| SCHEMBL20788827 | 1.00 | CA2 (0.32) | CA2MAPT | |
| SCHEMBL14498943 | 1.00 | CA2 (0.32) | CA2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3851441-B1 | PROCESS FOR THE PREPARATION OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO) PROPANAMIDE | HOFFMANN LA ROCHE (CH) | 2023-06-28 | — | — | EP | disclosed |
| EP-3851441-A1 | PROCESS FOR THE PREPARATION OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO) PROPANAMIDE | F. Hoffmann-La Roche AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| EP-3555107-B1 | PROCESS FOR THE PREPARATION OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO)PROPANAMIDE | HOFFMANN LA ROCHE (CH) | 2021-02-17 | — | — | EP | disclosed |
| US-10781219-B2 | Process for the preparation of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[F]imidazo[1,2-D][1,4]oxazepin-9-yl)amino) propanamide | GENENTECH, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20190292201-A1 | PROCESS FOR THE PREPARATION OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO) PROP AN AMIDE | GENENTECH, INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-9845299-B2 | Process for the preparation of a fluorolacton derivative | GILEAD PHARMASSET LLC (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845299-B2 | Process for the preparation of a fluorolacton derivative | GILEAD PHARMASSET LLC (US) | 2017-12-19 | — | — | US | disclosed |
| EP-2943475-B1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTON DERIVATIVE | GILEAD PHARMASSET LLC (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2943475-B1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTON DERIVATIVE | GILEAD PHARMASSET LLC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170183317-A1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTION DERIVATIVE | GILEAD SCIENCES, INC. | 2017-06-29 | — | — | US | disclosed |
| US-20150315165-A1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTON DERIVATIVE | HOFFMANN-LA ROCHE INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-20150315165-A1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTON DERIVATIVE | HOFFMANN-LA ROCHE INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-20150315165-A1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTON DERIVATIVE | HOFFMANN-LA ROCHE INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-20150141655-A1 | METHOD FOR THE PREPARATION OF THIADIAZOLES | AMGEN INC. | 2015-05-21 | — | — | US | disclosed |
| US-8912321-B2 | Preparation of nucleosides ribofuranosyl pyrimidines | GILEAD PHARMASSET LLC (US) | 2014-12-16 | — | — | US | disclosed |
| WO-2014108525-A1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTON DERIVATIVE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-17 | — | — | WO | disclosed |
| EP-2084174-B1 | PREPARATION OF NUCLEOSIDES RIBOFURANOSYL PYRIMIDINES | GILEAD PHARMASSET LLC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20100197939-A1 | PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF PREGABALIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| US-20100056770-A1 | PREPARATION OF NUCLEOSIDES RIBOFURANOSYL PYRIMIDINES | GILEAD PHARMASSET LLC | 2010-03-04 | — | — | US | disclosed |
| US-20080139802-A1 | Converting 2'-deoxy-2'-fluoro-2'-methyl-D-ribonolactones derivatives to 3-fluoro-3-methyl-2-chlorofuran compounds using chlorinating agent such as sulfuryl chloride, thionyl chloride or phosphorus oxychloride and tetrabutylammonium bromide | PHARMASSET, INC. | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781219-B2 | Process for the preparation of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[F]imidazo[1,2-D][1,4]oxazepin-9-yl)amino) propanamide | CACNA1D, CACNA1B, KCNMB4 | CA2 704/4885MAPT 3883/4885 |
| US-20080139802-A1 | Converting 2'-deoxy-2'-fluoro-2'-methyl-D-ribonolactones derivatives to 3-fluoro-3-methyl-2-chlorofuran compounds using chlorinating agent such as sulfuryl chloride, thionyl chloride or phosphorus oxychloride and tetrabutylammonium bromide | FBL, NSUN2, RNGTT | CA2 1915/4885MAPT 4852/4885 |
| US-20190292201-A1 | PROCESS FOR THE PREPARATION OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO) PROP AN AMIDE | CACNG4, KCNJ4, CYP2J2 | CA2 1560/4885MAPT 4047/4885 |
| US-20150141655-A1 | METHOD FOR THE PREPARATION OF THIADIAZOLES | GAPDH, TALDO1, HOGA1 | CA2 3620/4885MAPT 2582/4885 |
| US-20150315165-A1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTON DERIVATIVE | CYP2B6, CYP2F1, CYP3A5 | CA2 4852/4885MAPT 4618/4885 |
| US-20100197939-A1 | PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF PREGABALIN | GABRE, CYP2D6, GABRG2 | CA2 421/4885MAPT 2587/4885 |
| US-20100056770-A1 | PREPARATION OF NUCLEOSIDES RIBOFURANOSYL PYRIMIDINES | RNGTT, UMPS, NT5C3B | CA2 4871/4885MAPT 4531/4885 |
| US-20170183317-A1 | PROCESS FOR THE PREPARATION OF A FLUOROLACTION DERIVATIVE | CYP3A5, CYP2F1, CYP7A1 | CA2 4828/4885MAPT 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.